Cellmid Limited

ASX:CDY ISIN:AU000000CDY3

Cellmid Ltd ASX:CDYCellmid Limited (ASX:CDY) is an Australian life sciences company with a consumer health business and biotech assets. Advangen is Cellmid's wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated anti-aging products for hair, skin and body. Advangen has a range of FGF5 inhibitor hair growth products which are sold in Australia, Japan, USA and China. Advangen has a rich portfolio of hair growth and anti-aging hair care assets which include formulations of products on market, trademarks, patents and patent applications, proprietary assays and manufacturing processes.

The Company also holds the most comprehensive intellectual property around midkine, an important growth factor implicated in various diseases including cancer, inflammatory diseases, bone healing and autoimmune conditions. Lyramid, Cellmid's wholly owned subsidiary has been commercializing these promising drug technologies.

For further information, please see www.cellmid.com.au and www.evolisproducts.com.au

 
   

News

YPB Group Ltd (ASX:YPB) Agreement with Cellmid (ASX:CDY) to Access Chinese Health Market

🕔11/28/2017 1:44:47 PM 7062

Brand protection and customer connection solutions company YPB Group Ltd (ASX:YPB) and life sciences company Cellmid Limited (ASX:CDY) have signed an agreement to utilise the YPB CONNECT Consumer Connection SaaS platform in the marketing of Cellmid's evolis(R) hair loss products in China.

Read Full Article

Nature Publication Identifies Cellmid Limited's (ASX:CDY) Midkine as Important Target

🕔7/4/2017 8:54:20 AM 4269

Cellmid Limited (ASX:CDY) is pleased to advise that the highest ranked paper Nature has published the results of a significant study showing for the first time that midkine, around which the Company holds extensive intellectual property rights, is a crucial agent in the promotion of melanoma metastasis.

Read Full Article

Cellmid Limited (ASX:CDY) New Publication and Patent Application For Midkine Antibody

🕔6/24/2016 12:15:07 PM 5159

Cellmid Limited (ASX:CDY), in collaboration with a leading bone research group in Germany, has completed the first ever study showing that treatment with a midkine (MK) antibody accelerated bone fracture healing in an aged rodent model of the condition.

Read Full Article

Cellmid Limited (ASX:CDY) Chinese Distribution Agreement Signed with Beijing Based Company for Hair Loss Products

🕔1/29/2014 5:01:26 PM 6114

Cellmid Limited (ASX:CDY) advises that it has signed (via its wholly owned subsidiary Advangen Inc. (Japan)) a Chinese distribution agreement for its Lexilis Black(TM) and Jo-Ju(TM) brands with Beijing Huana Likang Biotechnology Co Ltd. The distribution agreement is exclusive for these brands in China subject to minimum performance requirements.

Read Full Article
###

6,586 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 7) (Last 30 Days: 33) (Since Published: 6586) 

Company Data

    Headquarters
  • Suite 204, Level 2
    55 Clarence Street
    Sydney NSW 2000
    Australia
  • Telephone
  • +61-2-9221-6830  
  • Fax
  • +61-2-9221-8535 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Healthcare 
  • Homepage
  • www.cellmid.com.au
  • E:
  • info@cellmid.com.au

Social Media